BidaskClub lowered shares of Insmed (NASDAQ:INSM) from a hold rating to a sell rating in a research report report published on Tuesday.
A number of other research firms also recently issued reports on INSM. Zacks Investment Research downgraded shares of Insmed from a hold rating to a sell rating in a report on Wednesday, February 28th. HC Wainwright restated a buy rating and set a $35.00 price objective on shares of Insmed in a report on Thursday, January 4th. Robert W. Baird restated a positive rating and set a $42.00 price objective (up previously from $32.00) on shares of Insmed in a report on Thursday, January 4th. Credit Suisse Group initiated coverage on shares of Insmed in a report on Wednesday, January 17th. They set a neutral rating and a $31.00 price objective for the company. Finally, ValuEngine upgraded shares of Insmed from a sell rating to a hold rating in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $36.67.
Shares of Insmed (NASDAQ:INSM) opened at $24.38 on Tuesday. The company has a market cap of $1,920.81, a PE ratio of -8.52 and a beta of 1.13. The company has a quick ratio of 8.72, a current ratio of 8.72 and a debt-to-equity ratio of 0.15. Insmed has a 1-year low of $11.49 and a 1-year high of $33.94.
Insmed (NASDAQ:INSM) last announced its earnings results on Friday, February 23rd. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.18). sell-side analysts expect that Insmed will post -3.64 EPS for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Nationwide Fund Advisors increased its stake in shares of Insmed by 20.2% in the third quarter. Nationwide Fund Advisors now owns 41,302 shares of the biopharmaceutical company’s stock worth $1,289,000 after purchasing an additional 6,947 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of Insmed in the third quarter valued at approximately $256,000. Schwab Charles Investment Management Inc. boosted its position in shares of Insmed by 23.5% in the third quarter. Schwab Charles Investment Management Inc. now owns 347,798 shares of the biopharmaceutical company’s stock valued at $10,855,000 after acquiring an additional 66,148 shares during the period. Alyeska Investment Group L.P. bought a new position in shares of Insmed in the third quarter valued at approximately $9,210,000. Finally, American International Group Inc. boosted its position in shares of Insmed by 28.1% in the third quarter. American International Group Inc. now owns 49,284 shares of the biopharmaceutical company’s stock valued at $1,538,000 after acquiring an additional 10,809 shares during the period. Hedge funds and other institutional investors own 99.08% of the company’s stock.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.